As Chief Scientific Officer, Dr. Hidalgo is responsible for the scientific vision of Absorption Systems, planning, executing, and managing the scientific and technical operations of the company. He co-founded Absorption Systems with his business partner Patrick Dentinger in 1996. His work in pharmaceutics and in vitro pharmacokinetic models formed the basis for the original premise of Absorption Systems, which was that validated, reliable preclinical test systems could identify drug candidates with appropriate drug-like properties and help predict success in the clinic. Dr. Hidalgo is famous among pharmaceutical scientists for pioneering the Caco-2 cell monolayer, an in vitro model that predicts human oral drug absorption. His seminal 1989 paper in the journal Gastroenterology has been cited more than 1300 times, and he was active in research on drug transporters in the 1990s, long before they became fashionable. It was his foresight and leadership that has resulted in CellPort Technologies, a panel of cell-based transporter assay systems whose development began even before the 2006 FDA draft guidance on drug interaction studies.
Dr. Hidalgo obtained his B.S. in pharmacy in his native Panama, followed by a Ph.D. in pharmaceutical sciences from the University of Southern California. The work for which he is best known was done during postdoctoral research in the Department of Pharmaceutical Chemistry at the University of Kansas. He then spent several very productive years at SmithKline Beecham and Rhone-Poulenc Rorer before starting Absorption Systems.
I.J. Hidalgo, T.J. Raub and R.T. Borchardt. Characterization of the human colon carcinoma cell line (Caco-2) as a model transport system of the intestinal epithelium .Gastroenterology 96:736-749, 1989
I.J. Hidalgo and R.T. Borchardt. Transport of bile acids in a human intestinal epithelial cell line, Caco-2. Biochim Biophys Acta 1035:97-103, 1990
C.H. Gochoco, F.M. Ryan, J. Miller, P.L. Smith and Ismael J. Hidalgo. Uptake and transepithelial transport of the orally-absorbed cephalosporin, cephalexin, in the human intestinal cell line, Caco-2. Int J Pharmaceutics 104:187-202, 1994
Ismael J. Hidalgo. Assessing the absorption of new pharmaceuticals . Current Topics in Medicinal Chemistry 1:385-401, 2001
Q. Wang, J.D Rager, K. Weinstein, P.S. Kardos, G. Dobson, J. Li, and Ismael J. Hidalgo. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharmaceutics 288:349-359, 2005
W. Zhang, J. Li, S.M. Allen, E. Weiskircher, Y. Huang, R.A. George, R.G. Fong, A. Owen, and Ismael J. Hidalgo. Silencing the breast cancer resistance protein expression and function in Caco-2 cells using lentiviral vector-based short hairpin RNA. Drug Metab Dispos 37(4):737-744, 2009
Business Development Manager